NutropinAq

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
20-07-2023
Valmisteyhteenveto Valmisteyhteenveto (SPC)
20-07-2023

Aktiivinen ainesosa:

somatropin

Saatavilla:

Ipsen Pharma

ATC-koodi:

H01AC01

INN (Kansainvälinen yleisnimi):

somatropin

Terapeuttinen ryhmä:

Pituitary and hypothalamic hormones and analogues

Terapeuttinen alue:

Turner Syndrome; Dwarfism, Pituitary

Käyttöaiheet:

Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion.Long-term treatment of growth failure associated with Turner syndrome.Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation.Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment.

Tuoteyhteenveto:

Revision: 20

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2001-02-15

Pakkausseloste

                                32
B.
PACKAGE LEAFLET
33
PACKAGE LEAFLET: INFORMATION FOR THE USER
NUTROPINAQ 10 MG/2 ML (30 IU) SOLUTION FOR INJECTION
somatropin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What NutropinAq is and what it is used for
2.
What you need to know before you use NutropinAq
3.
How to use NutropinAq
4.
Possible side effects
5.
How to store NutropinAq
6.
Contents of the pack and other information
1.
WHAT NUTROPINAQ IS AND WHAT IT IS USED FOR
NutropinAq contains somatropin which is a recombinant growth hormone
similar to the human’s
natural growth hormone made by your body. It is recombinant, meaning
it is made outside of the
body by a special process. Growth Hormone (GH) is a chemical messenger
made by a small gland in
your brain called the pituitary. In children it tells the body to
grow, help the bones to develop
normally and, in later adult life, GH helps to maintain a normal body
shape and metabolism.
IN CHILDREN, NUTROPINAQ IS USED:
•
When your body does not make enough growth hormone and for this reason
you are not
growing properly.
•
When you have Turner syndrome. Turner syndrome is a genetic
abnormality in girls (absence
of female sexual chromosome(s)) that prevents growth.
•
When your kidneys are damaged and they lose their ability to function
normally with an impact
on growth.
In adults NutropinAq is used for:
•
If your body does not make enough growth hormone as an adult. This can
start during adult life
or continue from when you were a child.
BENEFITS IF USING THIS MEDICINE
In childre
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
NutropinAq 10 mg/2 ml (30 IU) solution for injection.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml contains 5 mg of somatropin*
One cartridge contains 10 mg (30 IU) of somatropin
*
Somatropin is a human growth hormone produced in
_Escherichia coli _
cells by recombinant DNA
technology.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear and colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
_Paediatric population _
-
Long-term treatment of children with growth failure due to inadequate
endogenous growth
hormone secretion.
-
Long-term treatment of girls from 2 years old with growth failure
associated with Turner
syndrome.
-
Treatment of prepubertal children with growth failure associated with
chronic renal
insufficiency up to the time of renal transplantation.
_Adult population _
-
Replacement of endogenous growth hormone in adults with growth hormone
deficiency of
either childhood or adult-onset etiology. Growth hormone deficiency
should be confirmed
appropriately prior to treatment.
In adults with growth hormone deficiency the diagnosis should be
established depending on
the etiology:
_Adult-onset: _
The patient must have growth hormone deficiency as a result of
hypothalamic or
pituitary disease, and at least one other hormone deficiency diagnosed
(except for prolactin).
Test for growth hormone deficiency should not be performed until
adequate replacement
therapy for other hormone deficiencies have been instituted.
_Childhood-onset: _
Patients who have had growth hormone deficiency as a child should be
retested to confirm growth hormone deficiency in adulthood before
replacement therapy with
NutropinAq is started.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Diagnosis and therapy with somatropin should be initiated and
monitored by physicians who are
appropriately qualified and experienced in the diagnosis and
management of patients with the
therapeutic indic
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto bulgaria 20-07-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 06-06-2015
Pakkausseloste Pakkausseloste espanja 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto espanja 20-07-2023
Pakkausseloste Pakkausseloste tšekki 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto tšekki 20-07-2023
Pakkausseloste Pakkausseloste tanska 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto tanska 20-07-2023
Pakkausseloste Pakkausseloste saksa 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto saksa 20-07-2023
Pakkausseloste Pakkausseloste viro 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto viro 20-07-2023
Pakkausseloste Pakkausseloste kreikka 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto kreikka 20-07-2023
Pakkausseloste Pakkausseloste ranska 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto ranska 20-07-2023
Pakkausseloste Pakkausseloste italia 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto italia 20-07-2023
Pakkausseloste Pakkausseloste latvia 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto latvia 20-07-2023
Pakkausseloste Pakkausseloste liettua 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto liettua 20-07-2023
Pakkausseloste Pakkausseloste unkari 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto unkari 20-07-2023
Pakkausseloste Pakkausseloste malta 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto malta 20-07-2023
Pakkausseloste Pakkausseloste hollanti 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto hollanti 20-07-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 06-06-2015
Pakkausseloste Pakkausseloste puola 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto puola 20-07-2023
Pakkausseloste Pakkausseloste portugali 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto portugali 20-07-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 06-06-2015
Pakkausseloste Pakkausseloste romania 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto romania 20-07-2023
Pakkausseloste Pakkausseloste slovakki 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto slovakki 20-07-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 06-06-2015
Pakkausseloste Pakkausseloste sloveeni 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto sloveeni 20-07-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 06-06-2015
Pakkausseloste Pakkausseloste suomi 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto suomi 20-07-2023
Pakkausseloste Pakkausseloste ruotsi 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto ruotsi 20-07-2023
Pakkausseloste Pakkausseloste norja 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto norja 20-07-2023
Pakkausseloste Pakkausseloste islanti 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto islanti 20-07-2023
Pakkausseloste Pakkausseloste kroatia 20-07-2023
Valmisteyhteenveto Valmisteyhteenveto kroatia 20-07-2023

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia